Drugs

Papers
(The H4-Index of Drugs is 62. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression429
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”415
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments302
Bimekizumab for the Treatment of Psoriasis294
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations220
Targeting DNA Damage Response Deficiency in Thoracic Cancers191
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema176
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments162
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using146
Eftrenonacog Alfa: A Review in Haemophilia B123
Epcoritamab: First Approval119
Vorasidenib: First Approval118
Spesolimab for the Treatment of Generalized Pustular Psoriasis115
Aprocitentan: First Approval111
Teclistamab: First Approval109
New Therapies on the Horizon for Primary Biliary Cholangitis107
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences103
Cosibelimab: First Approval102
Upacicalcet: First Approval102
Drugs in Development to Manage Acute Pain101
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer97
Olipudase Alfa: First Approval97
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies97
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine93
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure92
Dostarlimab: First Approval91
Finerenone: First Approval88
Repotrectinib: First Approval88
Danicopan: First Approval88
Atogepant: First Approval87
Androgenetic Alopecia: Therapy Update85
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?85
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?83
Lenacapavir: First Approval83
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis81
Olverembatinib: First Approval79
Mosunetuzumab: First Approval78
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection78
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids77
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification75
Cancer Pain Treatment Strategies in Patients with Cancer75
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?75
Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections74
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology72
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes72
Correction to: Tapinarof Cream 1%: First Approval72
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer71
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough69
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis69
Sunvozertinib: First Approval69
Correction to: Prevention and Treatment of Monkeypox69
Dorzagliatin: First Approval68
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned68
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A67
The Place of Cannabinoids in the Treatment of Gynecological Pain67
Tovorafenib: First Approval65
Pozelimab: First Approval64
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options64
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab63
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy62
Correction to: Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis62
Correction to: Concizumab: First Approval62
0.10817408561707